Abstract
Methotrexate (MTX) is a first-line drug for the treatment of several rheumatic diseases. However, it is difficult to predict the response to this drug based on clinical manifestations. Although different mechanisms of action have been proposed for the antiinflammatory and immunosuppressive effects of MTX, the best characterized are blockade of the de novo synthesis of purines and pyrimidines, which inhibits DNA synthesis, and induction of adenosine release, which downregulates the effector functions of different immune cells. Thus, variants of the enzymes and other molecules involved in these metabolic pathways are expected to play a relevant role in the therapeutic effect or toxicity of MTX in patients with rheumatoid arthritis (RA). Accordingly, polymorphisms of the genes encoding these proteins have been widely associated with the response to or discontinuation of MTX. In addition, variants of the genes involved in the transportation of MTX inside and outside cells and in its metabolism have also been associated with the efficacy or toxicity of this drug in patients with RA. However, published results are contradictory, and no consensus regarding the best laboratory markers of MTX efficacy has been reached. Therefore, additional prospective studies with a large number of patients are necessary to identify the combination of genetic and nongenetic factors that can predict, with a reasonable level of confidence, the efficacy and toxicity of MTX in patients with RA.
Keywords: Rheumatoid arthritis, immunosuppressive therapy, single nucleotide polymorphisms, adenosine, pharmacogenomics.
Current Pharmaceutical Design
Title:Laboratory Biomarkers for Guiding Therapy with Methotrexate in Rheumatoid Arthritis
Volume: 21 Issue: 2
Author(s): Carlos Abud-Mendoza, Marco U. Martínez-Martínez, Adriana Monsivais-Urenda and Roberto Gonzalez- Amaro
Affiliation:
Keywords: Rheumatoid arthritis, immunosuppressive therapy, single nucleotide polymorphisms, adenosine, pharmacogenomics.
Abstract: Methotrexate (MTX) is a first-line drug for the treatment of several rheumatic diseases. However, it is difficult to predict the response to this drug based on clinical manifestations. Although different mechanisms of action have been proposed for the antiinflammatory and immunosuppressive effects of MTX, the best characterized are blockade of the de novo synthesis of purines and pyrimidines, which inhibits DNA synthesis, and induction of adenosine release, which downregulates the effector functions of different immune cells. Thus, variants of the enzymes and other molecules involved in these metabolic pathways are expected to play a relevant role in the therapeutic effect or toxicity of MTX in patients with rheumatoid arthritis (RA). Accordingly, polymorphisms of the genes encoding these proteins have been widely associated with the response to or discontinuation of MTX. In addition, variants of the genes involved in the transportation of MTX inside and outside cells and in its metabolism have also been associated with the efficacy or toxicity of this drug in patients with RA. However, published results are contradictory, and no consensus regarding the best laboratory markers of MTX efficacy has been reached. Therefore, additional prospective studies with a large number of patients are necessary to identify the combination of genetic and nongenetic factors that can predict, with a reasonable level of confidence, the efficacy and toxicity of MTX in patients with RA.
Export Options
About this article
Cite this article as:
Abud-Mendoza Carlos, Martínez-Martínez U. Marco, Monsivais-Urenda Adriana and Gonzalez- Amaro Roberto, Laboratory Biomarkers for Guiding Therapy with Methotrexate in Rheumatoid Arthritis, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825123632
DOI https://dx.doi.org/10.2174/1381612820666140825123632 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Chondrocyte Survival and Matrix Synthesis During Hypoxia
Current Rheumatology Reviews Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
Current Drug Targets The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Statistical Identification of Gene-gene Interactions Triggered By Nonlinear Environmental Modulation
Current Genomics Gene Therapy for Rheumatoid Arthritis: Recent Advances
Current Gene Therapy Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
Current Vascular Pharmacology Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Some Developments Regarding Functional Food Products (Functional Foods)
Current Nutrition & Food Science Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Damage-Associated Molecular Patterns – Emerging Targets for Biologic Therapy of Childhood Arthritides
Inflammation & Allergy - Drug Targets (Discontinued) Transitional Connective Tissue Diseases: Description of Four Cases
Current Rheumatology Reviews Second Messenger Modulation: A Novel Target of Future Antidepressants?
Current Medicinal Chemistry Mikuliczs Disease and its Extraglandular Lesions
Current Immunology Reviews (Discontinued) Protein Regulators of Eicosanoid Synthesis: Role in Inflammation
Current Protein & Peptide Science Nanoemulsions for Skin Targeting: Present Status and Future Prospects
Drug Delivery Letters Complications Encountered with Total Hip Arthroplasty in Rheumatoid Patients
Current Rheumatology Reviews Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy